Cargando…

Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice

Inotropes are pharmacological agents that are indicated for the treatment of patients presenting with acute heart failure (AHF) with concomitant hypoperfusion due to decreased cardiac output. They are usually administered for a short period during the initial management of AHF until haemodynamic sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Bistola, Vasiliki, Arfaras-Melainis, Angelos, Polyzogopoulou, Eftihia, Ikonomidis, Ignatios, Parissis, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848944/
https://www.ncbi.nlm.nih.gov/pubmed/31768269
http://dx.doi.org/10.15420/cfr.2019.11.2
_version_ 1783469108148305920
author Bistola, Vasiliki
Arfaras-Melainis, Angelos
Polyzogopoulou, Eftihia
Ikonomidis, Ignatios
Parissis, John
author_facet Bistola, Vasiliki
Arfaras-Melainis, Angelos
Polyzogopoulou, Eftihia
Ikonomidis, Ignatios
Parissis, John
author_sort Bistola, Vasiliki
collection PubMed
description Inotropes are pharmacological agents that are indicated for the treatment of patients presenting with acute heart failure (AHF) with concomitant hypoperfusion due to decreased cardiac output. They are usually administered for a short period during the initial management of AHF until haemodynamic stabilisation and restoration of peripheral perfusion occur. They can be used for longer periods to support patients as a bridge to a more definite treatment, such as transplant of left ventricular assist devices, or as part of a palliative care regimen. The currently available inotropic agents in clinical practice fall into three main categories: beta-agonists, phosphodiesterase III inhibitors and calcium sensitisers. However, due to the well-documented potential for adverse events and their association with increased long-term mortality, physicians should be aware of the indications and dosing strategies suitable for different types of patients. Novel inotropes that use alternative intracellular pathways are under investigation, in an effort to minimise the drawbacks that conventional inotropes exhibit.
format Online
Article
Text
id pubmed-6848944
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Radcliffe Cardiology
record_format MEDLINE/PubMed
spelling pubmed-68489442019-11-25 Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice Bistola, Vasiliki Arfaras-Melainis, Angelos Polyzogopoulou, Eftihia Ikonomidis, Ignatios Parissis, John Card Fail Rev Clinical Practice Inotropes are pharmacological agents that are indicated for the treatment of patients presenting with acute heart failure (AHF) with concomitant hypoperfusion due to decreased cardiac output. They are usually administered for a short period during the initial management of AHF until haemodynamic stabilisation and restoration of peripheral perfusion occur. They can be used for longer periods to support patients as a bridge to a more definite treatment, such as transplant of left ventricular assist devices, or as part of a palliative care regimen. The currently available inotropic agents in clinical practice fall into three main categories: beta-agonists, phosphodiesterase III inhibitors and calcium sensitisers. However, due to the well-documented potential for adverse events and their association with increased long-term mortality, physicians should be aware of the indications and dosing strategies suitable for different types of patients. Novel inotropes that use alternative intracellular pathways are under investigation, in an effort to minimise the drawbacks that conventional inotropes exhibit. Radcliffe Cardiology 2019-11-04 /pmc/articles/PMC6848944/ /pubmed/31768269 http://dx.doi.org/10.15420/cfr.2019.11.2 Text en Copyright © 2019, Radcliffe Cardiology https://creativecommons.org/licenses/by-nc/4.0/legalcode This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.
spellingShingle Clinical Practice
Bistola, Vasiliki
Arfaras-Melainis, Angelos
Polyzogopoulou, Eftihia
Ikonomidis, Ignatios
Parissis, John
Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice
title Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice
title_full Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice
title_fullStr Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice
title_full_unstemmed Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice
title_short Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice
title_sort inotropes in acute heart failure: from guidelines to practical use: therapeutic options and clinical practice
topic Clinical Practice
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848944/
https://www.ncbi.nlm.nih.gov/pubmed/31768269
http://dx.doi.org/10.15420/cfr.2019.11.2
work_keys_str_mv AT bistolavasiliki inotropesinacuteheartfailurefromguidelinestopracticalusetherapeuticoptionsandclinicalpractice
AT arfarasmelainisangelos inotropesinacuteheartfailurefromguidelinestopracticalusetherapeuticoptionsandclinicalpractice
AT polyzogopouloueftihia inotropesinacuteheartfailurefromguidelinestopracticalusetherapeuticoptionsandclinicalpractice
AT ikonomidisignatios inotropesinacuteheartfailurefromguidelinestopracticalusetherapeuticoptionsandclinicalpractice
AT parissisjohn inotropesinacuteheartfailurefromguidelinestopracticalusetherapeuticoptionsandclinicalpractice